title: Triamcinolone-assisted removal of internal limiting membrane enhances the effect of vitrectomy for diabetic macular edema.
abstract: OBJECTIVE
  To evaluate the efficacy of internal limiting membrane (ILM) peeling during vitrectomy to treat diabetic macular edema (DME).
  
  
  METHODS
  In this nonrandomized study, we retrospectively analyzed the medical charts of 107 eyes that had undergone three-port vitrectomy to treat DME. The ILM was peeled in 65 eyes and not peeled in 42 eyes (ILM ON group). Indocyanine green (ICG) was used on 36 eyes (ICG group) and triamcinolone acetonide (TA) on 29 eyes (TA group) to make the ILM more visible.
  
  
  RESULTS
  In all groups, the mean foveal thickness was significantly decreased after surgery. Visual acuity (VA) improved gradually after the surgery and was significantly better than the preoperative VA at 6 months in the ICG group and at 3 months in the TA group. Compared with the ILM ON group eyes, the eyes in the TA group had significantly better improvement of VA.
  
  
  CONCLUSIONS
  TA-assisted ILM peeling may improve the VA outcome to treat DME.
authors.affiliation: Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Tomomi
authors.initials: T
authors.lastname: Yamakoshi
authors.forename: Shu
authors.initials: S
authors.lastname: Kachi
authors.forename: Jiro
authors.initials: J
authors.lastname: Sugita
authors.forename: Tetsu
authors.initials: T
authors.lastname: Asami
authors.forename: Kohei
authors.initials: K
authors.lastname: Ishikawa
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Ito
authors.forename: Hiroko
authors.initials: H
authors.lastname: Terasaki
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004396:Coloring Agents / Q000627:therapeutic use; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D007208:Indocyanine Green / Q000627:therapeutic use; D008269:Macular Edema / Q000209:etiology / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000187:drug effects* / Q000473:pathology; D012189:Retrospective Studies; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity; D014821:Vitrectomy / Q000379:methods*
chemical_list: D000893:Anti-Inflammatory Agents; D004396:Coloring Agents; D014222:Triamcinolone Acetonide; D007208:Indocyanine Green